Cotreatment With Neferine Enhances Activity Of Imatinib Mesylate Sensitive On Chronic Myelogenous Leukemia Cells

OBJECTIVE:We determined the chemosensitivity effect of neferine's antitumor activity of STI571 on the chronic myelogenous leukemia (CML) cells.METHODS:Cytotoxicity was determined by improved MTT assay.we detect the changes of p210Bcr-abl mRNA and protein expression by RT-PCR and Western blotting respectively.RESULTS:(1)The results clearly indicate that Neferine inhibited CML cell growth with time and dose-dependent manners and Cotreatment with 8 umol/Lneferine which is the more effective in CML cells with a lower IC50 value of 0.16±0.02 compared to an IC50 value of 0.70±0.10μmol·L-1 in CML cells. Further studies revealed Neferine (2)The application of single drug of Nef, As2O3 has no effect on p210Bcr-abl mRNA expression in CML cell lines.Nef in combination with STI571 begin to downregulate p210Bcr-abl mRNA expression of CML cell lines at 48h and this effect is significant(P<0.05).The application of single drug of Nef has no effect on p210Bcr-abl expression in CML cell lines and in combination with STI571 can downregulate P210Bcr-abl expression in cells and this effect is significant(P<0.05).CONCLUSIONS: Nef has a potency of anticancer to the CMLcells,and the anticancer activity was dose-related. (2) Nef can enhanced the effects of STI571 on down-regulate p210Bcr-abl mRNA and p210Bcr-abl protein expression.Nef is able to potentiate the anticancer function of STI571.